Watchlist Price Alert

Unity Biotechnology Inc. (UBX)

NASDAQ: UBX · Real-Time Price · USD

0.81

-0.00 (-0.14%)

At close: Jun 17, 2025, 10:47 AM

-0.14% (1D)

Bid	0.81
Market Cap	13.87M
Revenue (ttm)	n/a
Net Income (ttm)	-27.5M
EPS (ttm)	-1.63
PE Ratio (ttm)	-0.49
Forward PE	-0.97
Analyst	Hold

Ask	0.87
Volume	41,711
Avg. Volume (20D)	305,053
Open	0.83
Previous Close	0.81
Day's Range	0.79 - 0.84
52-Week Range	0.66 - 3.10
Beta	1.06

About UBX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol UBX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for UBX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-4.46%

UBX stock has given up its prior loss. Unity Biote... Unlock content with Pro Subscription

1 month ago

-4.46%

Unity Biotechnology shares are trading lower after the company announced 36-week results from its Phase 2b ASPIRE clinical trial.

News

2 months ago · zacks.com

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.

2 months ago · benzinga.com

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study.